Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H47NO4S |
| Molecular Weight | 493.742 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@@]1(C)[C@H](C)CC3
InChI
InChIKey=UURAUHCOJAIIRQ-QGLSALSOSA-N
InChI=1S/C28H47NO4S/c1-8-26(6)17-22(33-23(31)18-34-16-15-29(9-2)10-3)27(7)19(4)11-13-28(20(5)25(26)32)14-12-21(30)24(27)28/h8,19-20,22,24-25,32H,1,9-18H2,2-7H3/t19-,20+,22-,24+,25+,26-,27+,28+/m1/s1
| Molecular Formula | C28H47NO4S |
| Molecular Weight | 493.742 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Tiamulin is a diterpene antimicrobial with a pleuromutilin chemical structure similar to that of
valnemulin. The activity of tiamulin is largely confined to gram-positive micro-organisms and
mycoplasma. Tiamulin acts by inhibiting protein synthesis at the ribosomal level. In veterinary
medicine, tiamulin is used for treatment and prophylaxis of dysentery, pneumonia and
mycoplasmal infections in pigs and poultry. Tiamulin is available as a 2, 10 or 20% premix for
pigs and poultry, a 12.5% solution or 45% water soluble powder for addition to drinking water
for pigs and poultry, or a 10% injectable formulation for pigs. Tiamulin inhibits protein synthesis by targeting the 50S bacterial ribosomal subunit and binding to peptidyl transferase, the enzyme responsible for forming peptide bonds between amino acids.
Originator
Sources: https://www.aasv.org/news/story.php?id=1601 | http://www.chemdrug.com/article/8/3285/16420569.html
Curator's Comment: # Novartis
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5957 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28399915 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | DENAGARD Approved UseFor the treatment of swine dysentery associated with Treponema hyodysenteriae and swine pneumonia due to Actinobacillus pleuropneumoniae susceptible to tiamulin. Launch Date1993 |
|||
| Curative | DENAGARD Approved UseFor the treatment of swine dysentery associated with Treponema hyodysenteriae and swine pneumonia due to Actinobacillus pleuropneumoniae susceptible to tiamulin. Launch Date1993 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.5 ug/mL single, respiratory Studied dose Dose: 0.5 ug/mL Route: respiratory Route: single Dose: 0.5 ug/mL Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Other AEs: QT interval prolonged, Ventricular tachyarrhythmia... Other AEs: QT interval prolonged Sources: Ventricular tachyarrhythmia |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| QT interval prolonged | 0.5 ug/mL single, respiratory Studied dose Dose: 0.5 ug/mL Route: respiratory Route: single Dose: 0.5 ug/mL Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
| Ventricular tachyarrhythmia | 0.5 ug/mL single, respiratory Studied dose Dose: 0.5 ug/mL Route: respiratory Route: single Dose: 0.5 ug/mL Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 149.0 |
no | |||
Page: 152.0 |
no | |||
| yes [IC50 1.6 uM] | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 151.0 |
inconclusive |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 2.0 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetic/Pharmacodynamic Profiles of Tiamulin in an Experimental Intratracheal Infection Model of Mycoplasma gallisepticum. | 2016 |
|
| Change in antimicrobial susceptibility of Mycoplasma gallisepticum field isolates. | 2011-06-02 |
|
| Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. | 1997-09 |
|
| Inhibitory effects of tiamulin on contractile and electrical responses in isolated thoracic aorta and cardiac muscle of guinea-pigs. | 1992-09 |
|
| The inhibitory effect of tiamulin on high K(+)-induced contraction in guinea pig intestinal smooth muscle. | 1991-12 |
Patents
Sample Use Guides
Pigs and poultry: Dietary doses are 100 to 200 mg/kg
feed for 5 to 10 days, and up to 6 weeks at 50 mg/kg feed for pigs, and 160 to 320 mg/kg feed for
poultry. In drinking water, doses of 4 to 25 mg/kg bw for up to 1 week are used for pigs, and
doses of 30 to 60 mg/kg bw for 3 to 5 days in poultry. Intramuscular doses of 10 to 20 mg/kg bw
may be given daily for up to 5 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9303412
Tiamulin was most active against mycoplasma strains of eight species isolated from poultry (MICs at which 90% of the isolates were inhibited [MIC90s], 0.025 to 0.25 ug/ml).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:11:54 GMT 2025
by
admin
on
Mon Mar 31 18:11:54 GMT 2025
|
| Record UNII |
E38WZ4U54R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 520.2455
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
||
|
WHO-VATC |
QJ01XQ01
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
||
|
NCI_THESAURUS |
C258
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
||
|
CFR |
21 CFR 556.732
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
||
|
CFR |
21 CFR 558.612
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
E38WZ4U54R
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
DTXSID2046701
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
3932
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
C014224
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
TIAMULIN
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
SUB11005MIG
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
1546410
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | RxNorm | ||
|
1667355
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
7026
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
44137
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
55297-95-5
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
C84207
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
259-580-0
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
DB11468
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
m10844
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000082177
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
CHEMBL498466
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
E38WZ4U54R
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY | |||
|
656958
Created by
admin on Mon Mar 31 18:11:54 GMT 2025 , Edited by admin on Mon Mar 31 18:11:54 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |